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Objectives. This study reports our clinical experience with
transcatheter closure of secundum atrial septal defects (ASDs) in
children, using the Amplatzer, a new occlusion device.
Background. None of the devices previously used for transcath-
eter closure of interatrial communications has gained wide accep-
tance.
Methods. We examined the efficacy and safety of the Amplatzer,
a new self-centering septal occluder that consists of two round
disks made of Nitinol wire mesh and linked together by a short
connecting waist. Sixteen patients with secundum ASD met estab-
lished two- and three-dimensional echocardiographic and cardiac
catheterization criteria for transcatheter closure. The Amplatzer’s
size was chosen to be equal to or 1 mm less than the stretched
diameter. The device was advanced transvenously into a 7F long
guiding sheath and deployed under fluoroscopic and ultrasound
guidance. Once its position was optimal, it was released.
Results. The mean ASD diameter by transesophageal echocar-
diography was 14.1 6 2.3 mm and was significantly smaller (p <
0.001) than the stretched diameter of the ASD (16.8 6 2.4 mm).
The mean device diameter was 16.6 6 2.3 mm. No complications
were observed. After deployment of the prosthesis, there was no
residual shunt in 13 (81.3%) of 16 patients. In three patients there
was trivial residual shunt immediately after the procedure that
had disappeared in two of them at the 3-month follow-up.
Conclusions. The Amplatzer is an efficient prosthesis that can
be safely applied in children with secundum ASD. However, a
study including a large number of patients and a longer follow-up
period are required before this technique can be widely used.
(J Am Coll Cardiol 1998;31:1110–6)
©1998 by the American College of Cardiology
Although surgical repair of interatrial communications is a
safe, widely accepted procedure with negligible mortality, it is
associated with morbidity, discomfort and a thoracotomy scar
(1). As an alternative to surgery, a variety of devices for
transcatheter closure of atrial septal defects (ASDs) have been
developed over the past 20 years, but none has gained wide
acceptance. Large delivery sheaths, cumbersome implantation
techniques, inability to recapture, structural failure, dislodg-
ment and embolization of the device are some of the limita-
tions of previously prescribed techniques (2–12). This study
describes our experience with transcatheter closure of ASDs in
children using a new self-expanding, self-centering and repo-
sitionable device, the Amplatzer. This device was tested at the
University of Minnesota and has been evaluated in animal in
vivo experimental studies (13) with promising results that
support initiation of clinical trials.
Methods
Device and delivery system. The Amplatzer and delivery
system have been described in detail in previous reports (13).
In brief, this device consists of two self-expandable round disks
made of 0.004- to 0.005-in. Nitinol wire mesh that are linked
together by a short (4 mm) connecting waist, corresponding to
the thickness of the atrial septum (Fig. 1). The left atrial disk
extends 7 mm radially around the connecting waist and the
right disk 5 mm. The left disk is slightly larger than the right
because of the higher left atrial pressure. Both disks are angled
slightly toward each other to ensure firm contact with the atrial
septum. The prosthesis is filled with Dacron fabric to facilitate
thrombosis. Prostheses are currently available in sizes ranging
from 4 to 20 mm at increments of 1 mm. The device is attached
by a microscrew mechanism onto a 0.038-in. delivery cable
made of stainless steel (Fig. 2A). It is loaded into a long 6F or
7F (occluders .10 mm) introducer sheath. For introduction
into the delivery sheath the device is pulled into a loader (Fig.
2B).
Patients. Twenty-two patients from 4 to 14 years of age
(median 9.2) with a secundum ASD awaiting surgical closure
were evaluated at our institution with two-dimensional and
color Doppler echocardiography. Eighteen of these patients
met echocardiographic criteria for transcatheter closure with
the Amplatzer device (AGA Medical Corporation, Golden
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Valley, MN) and subsequently underwent device implantation.
One of the patients had a significant residual defect after
surgical ASD closure and another had severe valvar pulmonary
stenosis associated with a secundum ASD.
All devices were implanted under research protocol ap-
proved by the Ethical Committee on Clinical Investigation of
“Aghia Sophia” Children’s Hospital, Athens. The Amplatzer
prosthesis was approved by the Office of Compliance, Center
for Devices and Radiological Health of the U.S. Food and
Drug Administration for export and investigational use. In-
formed parental consent was obtained for each patient.
Study protocol. Patients were screened by transthoracic
two-dimensional Doppler echocardiography with multiple sub-
xyphoid and precordial windows. Five patients with poor
transthoracic echocardiographic windows were further evalu-
ated with biplane transesophageal echocardiography. In the
last 10 patients transthoracic three-dimensional echocardiog-
raphy was also performed in order to define the spatial
anatomy of the ASDs. Patient inclusion criteria were 1) the
presence of an ostium secundum ASD, 2) left to right shunting
across the ASD, 3) maximal ASD diameter of ,20 mm, 4) a
distance of .5 mm from the margins of the defect to the mitral
and tricuspid valves, superior vena cava, right upper pulmo-
nary vein and coronary sinus, and 5) dilation of the right
ventricle with evidence of right ventricular volume overload.
Patients who met these criteria were further evaluated with
transesophageal echocardiography under general anesthesia
before cardiac catheterization. All patients underwent balloon
sizing to establish the stretched diameter of the ASD, which
was then used to select the appropriate size of the occluding
device. In patients with a balloon-stretched ASD diameter of
.21 mm closure was not undertaken. The device size was
selected to be equal or 1 mm less than the measured stretched
diameter.
Procedure. The patients were intubated and placed under
general anesthesia. After percutaneous puncture of the femo-
ral vein, a complete hemodynamic evaluation was performed
with pressure and saturation measurements taken in all cardiac
chambers. A pulmonary arteriogram was performed in a 35°
left axial oblique projection with 35° cranial angulation (four
chamber view) with an 8F Berman angiographic balloon
catheter (Arrow International Inc., Reading, PA) to rule out
anomalous pulmonary venous connections. Subsequently, con-
trast medium was injected at the junction of the left atrium
with the right upper pulmonary vein to delineate the anatomy
of the ASD. A 7F balloon-tipped end-hole catheter (Arrow
Abbreviations and Acronyms
ASD 5 atrial septal defect
CI 5 confidence interval
Figure 1. Amplatzer septal occluder made of 0.005-in. Nitinol wire
tightly woven into two round disks with a 4-mm connecting waist
(arrowheads). Arrow indicates the negative microscrew adaptor
mounted on the right atrial disk.
Figure 2. A, Delivery cable of the Amplatzer prosthesis (arrowheads).
Vertical arrow indicates the plastic vice that facilitates release (un-
screwing) of the device. B, Adaptor tube (arrowheads) used for
introduction of the device into the delivery sheath.
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International Inc., Reading, PA) was manipulated through the
ASD into the left upper or lower pulmonary vein. Using an
exchange 260 cm, J-tipped guidewire, a 27-mm, 100-cm occlu-
sion balloon catheter (Meditech, Watertown, MA) was intro-
duced into the left atrium. The balloon catheter was inflated
with various increments of contrast medium and pulled across
the ASD under fluoroscopic and transesophageal echocardio-
graphic observation. A slight deformity of the sizing balloon
was used to determine the stretched diameter. The sizing
balloon was then removed, reinflated with the same amount of
contrast medium and passed through calibrated openings in a
sizing plate to determine the stretched diameter. The occlud-
ing device was selected to be the same size or 1 mm smaller
than the stretched diameter. The device size refers to the
diameter of the connecting waist.
The device was screwed to the tip of the delivery cable,
immersed in normal saline and drawn into the loader. A Y
connector was applied to the proximal end of the loader to
allow flushing with saline. A 7F, long guiding sheath and
dilator were advanced over the guidewire through the commu-
nication into the left atrium. The correct position of the
delivery sheath was verified by a test injection of contrast
medium. The loader with the collapsed device was then
advanced into the guiding catheter by pushing the delivery
cable (Fig. 3A). Under fluoroscopic (Fig. 3B) and ultrasonic
guidance, the left atrial disk was deployed and pulled gently
against the atrial septum, which was both felt and observed by
transesophageal echocardiography. Using gentle tension on
the delivery cable, the sheath was pulled back and the right
atrial disk was deployed (Fig. 3C). To and fro motion of the
delivery cable ensured a secure position across the ASD. This
was also observed by two-dimensional Doppler echocardiog-
raphy and fluoroscopy. Biplane transesophageal color Doppler
echocardiography was performed after device deployment to
check for the presence of residual shunt, possible obstruction
to systemic or pulmonary venous return and impairment of the
atrioventricular valves. Once its position was optimal, the
device was released by counterclockwise rotation of the deliv-
ery cable. After release of the Amplatzer both color Doppler
echocardiography and pulmonary angiography were per-
formed to detect any residual shunt (Fig. 3D and 4). In 10
patients accurate device position was confirmed by en-face
three-dimensional echocardiographic views from the right and
left atrium. Intravenous antibiotics (ampicillin 200 mg/kg body
weight and gentamycin 5 to 6 mg/kg) were delivered immedi-
ately after placement of the prosthesis and repeated at 8 and
16 h, for a total of three doses. All patients were discharged on
the day after the procedure with instructions to take aspirin 3
to 5 mg/kg daily for 3 months.
Follow-up studies. A chest radiograph and a transthoracic
color Doppler echocardiographic study were performed on all
patients at 24 h after the procedure and at 1 and 3 months
Figure 3. Cineradiographic frames (A to C) and angiogram (D) in
four-chamber view showing steps of atrial septal defect closure with
the Amplatzer: A, Advancement of the device through a 7F delivery
sheath into the left atrium. B, Deployment of the left atrial disk. C,
Deployment of the right atrial disk. D, Levo-phase of pulmonary
arteriogram after release of the device, showing complete closure and
a good position of both disks across the atrial septum.
Figure 4. Transesophageal two-dimensional and color Doppler images
of the atrial septum obtained from short-axis views before (top) and
immediately after (bottom) implantation of the Amplatzer prosthesis.
Note good position of the device (white arrows) with no evidence of
residual shunt by color Doppler. D 5 diameter of the defect; LA 5 left
atrium; RA 5 right atrium.
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later. A transesophageal echocardiographic study was sched-
uled for the 6-month follow-up.
Persistent atrial shunts were angiographically (immediately
after the procedure) and echocardiographically defined as
“foaming” (minor diffuse leak through the Dacron fabric),
trivial (faint right atrial opacification and jet ,1 mm in
diameter), small (minor right atrial opacification and jet 1 to
2 mm in diameter), moderate (obvious right atrial opacifica-
tion and jet 3 to 4 mm in diameter) and large (intense right
atrial opacification and jet .4 mm in diameter).
Statistical analysis. Results are expressed as mean value 6
SD, with confidence intervals given where applicable. The
Student paired t test was used to compare transesophageal
echocardiographic and balloon-stretched ASD diameter. A p
value ,0.05 was considered statistically significant.
Results
Two patients had a balloon-stretched ASD diameter
.21 mm and were excluded from transcatheter closure. Trans-
catheter closure of secundum ASDs was carried out in the
remaining 16 patients. Descriptive statistics and outcome for
all patients are shown in Table 1. Delivery of the device was
successful in all patients. The mean ASD diameter determined
by transesophageal two-dimensional echocardiography was
14.1 6 2.3 mm (range 10 to 19) and was significantly smaller
(p , 0.001) than the stretched diameter of the ASD measured
by balloon sizing (16.8 6 2.4 mm; range 12 to 21). The mean
device diameter was 16.6 6 2.3 mm (range 12 to 20). There was
left to right shunt across the ASD in all patients, both by color
Doppler echocardiography and oximetry at the time of cathe-
terization. The pulmonary/systemic flow ratio (Qp/Qs) varied
between 1.5 and 2.9 (mean 2.01 6 0.46).
Misplacement of the device occurred in one patient and was
successfully managed by withdrawing both discs into the deliv-
ery sheath and redeploying the device. No complications were
observed as a result of the procedure. After release of the
prosthesis, pulmonary artery cineangiography and color Dopp-
ler echocardiography revealed no residual shunt in 13 (81.3%,
95% confidence interval [CI] 54.35% to 95.95%) of 16 patients.
“Foaming,” documented by both angiography and transesoph-
ageal echocardiography, was present in five patients (31.3%)
but disappeared within 15 to 20 min. In three patients there
was a trivial residual shunt immediately after the procedure.
The device waist diameter used in these patients was 1 mm less
than the stretched ASD diameter. In the patient with coexist-
ing valvar pulmonary stenosis, a successful balloon pulmonary
valvuloplasty was performed before transcatheter closure of
the ASD.
Fluoroscopy time was 20.3 6 3.5 min (range 14 to 26) and
total procedure time was 67.5 6 8.1 min (range 55 to 82).
Immediate transesophageal echocardiographic examination
revealed no obstruction to the superior and inferior venae
cavae, the coronary sinus or the right upper pulmonary vein.
Neither retention disk was in contact with the mitral or the
tricuspid valve and valve regurgitation was not observed.
A good quality image for three-dimensional echocardio-
graphic reconstruction was obtained in 9 of 10 patients who
Table 1. Pertinent Patient Data* and Outcome After Transcatheter Atrial Septal Defect Closure With
the Amplatzer Prosthesis
Pt No./
Age (yr) Wt (kg)
ASD Diameter
Device Size
(mm)
Outcome
TEE
(mm)
Stretched
(mm)
Immediate
(A 1 TED)
24 h
(TTD)
1 mo
(TTD)
3 mo
(TTD)
1/4 15 16 19 18 TS TS TS TS
2/10 30 13 15 15 C C C C
3/14 70 14 17 17 C C C C
4/12 36 12 13 13 C C C C
5/5 17 14 16 16 C C C C
6/9 33 13 15 14 TS TS C C
7/14 48 10 12 12 C C C C
8/14 65 16 18 18 C C C C
9/13 55 19 21 20 TS TS C C
10/6 27 13 17 17 C C C C
11/4 20 11 15 15 C C C C
12/9 27 17 20 20 C C C C
13/10 32 15 18 18 C C C C
14/9 35 13 17 17 C C C C
15/8 29 15 19 19 C C C C
16/6 20 14 16 16 C C C C
9.2 6 3.5† 35 6 16.5† 14.1 6 2.3† 16.8 6 2.4† 16.6 6 2.3†
*Statistical analysis was performed comparing the TEE diameter and the stretched diameter of the ASDs. †Mean
value 6 SD. A 5 angiogram; ASD 5 atrial septal defect; C 5 complete closure; Pt 5 patient; TED 5 transesophageal
color Doppler; TEE 5 transesophageal echocardiography; TS 5 trivial residual shunt; TTD 5 transthoracic color
Doppler; Wt 5 weight.
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were evaluated with transthoracic three-dimensional echocar-
diography. In these patients we were able to see both atrial
disks from the right and left atrial views and exclude obstruc-
tion of the superior vena cava, right upper pulmonary vein or
coronary sinus. In addition, the proximity of both disks to the
atrioventricular valves was evaluated. In all these patients the
device was in the appropriate position and no interference with
the surrounding cardiac structures was observed (Fig. 5).
Follow-up echocardiographic data were available in all 16
patients at 1 and 3 months after the procedure. There was no
evidence of residual shunt in 15 (93.75%, 95% CI 69.77% to
99.84%) of the 16 patients. In one of the three patients with a
trivial residual shunt immediately after the procedure the
shunt was still present at the 3-month follow-up. No compli-
cations were observed during short-term follow-up.
Discussion
Although several reports of successful transcatheter closure
of secundum ASDs have appeared in the literature, the
procedure has not yet achieved widespread clinical use and it
is still under investigation. This is most likely because of
difficulties related to the implantation technique and draw-
backs in the design of the occlusion devices (2–12).
In the present study a new ASD occluder, the Amplatzer,
was employed for transcatheter closure of ASDs (ranging from
12 to 21 mm) in 16 patients. Complete occlusion was achieved
in 15 (94%) of 16 patients, with no complications during the
procedure or at short-term follow-up. It appears that the
efficacy and safety of the technique are predominantly owing to
the simplicity of the deployment and the novel design of the
Amplatzer septal occluder.
Comparison with other devices. The Amplatzer was de-
signed to overcome many of the drawbacks of previously used
devices. Previous devices include the clamshell septal occluder
(3,4), the Sideris prosthesis (buttoned device) (5,7), the atrial
septal defect occlusion system (8,9), the Das Angel Wing
(10,11) and the Pavcnik monodisk (12). Besides the Sideris
prosthesis, which is delivered through an 8F sheath for devices
up to 40 mm, all other occluders require a large 9F to 13F
sheath, which makes their application difficult or impossible in
small children. The Amplatzer is delivered through a 6F to 7F
sheath, which facilitates its use even in infancy. Moreover, the
other devices are limited in that they require a large device size
(2- to 2.5-fold the stretched ASD diameter) to ensure complete
closure if they are not perfectly centered. The Amplatzer is a
self-centering prosthesis and the round retention disks extend
radially beyond the defect, resulting in a much smaller overall
size than all other devices. The Das Angel Wing and the
Pavcnik monodisk are the only currently used devices with a
self-centering mechanism (10,12). Of these two devices, the
Pavcnik monodisk has the advantage of requiring a rather
small device/ASD diameter ratio but it offers a questionable
centering mechanism and there is very limited clinical experi-
ence. The Das Angel Wing prosthesis has a more reliable
centering mechanism, but not during deployment, and conse-
quently, the retention skirts have to remain oversized.
In contrast to the atrial septal occluders that accomplish
closure of the ASD by the retention flanges (patches), the
Amplatzer uses a short (4 mm) communicating waist to stent
the defect, forcing blood flow through a network of highly
thrombogenic polyester material. Indeed, we observed “foam-
ing” with transesophageal echocardiography and angiography
immediately after deployment, which completely disappeared
within 15 to 20 min. Moreover, the inward inclination of both
retention disks allows firm contact with the atrial septum,
which enhances endothelialization and reduces the risk of
residual shunting. The previously reported incidence of resid-
ual shunting (20% to 39%) is much higher than in the present
study (6%) (4,7,9,11).
Selection of the appropriate device size is of paramount
importance for effective and safe ASD closure regardless of
Figure 5. A, Four-chamber, three-dimensional view
of the patient with a residual, slightly eccentric ASD
after surgical closure and placement of the Am-
platzer. Both round disks (arrowheads) can be
simultaneously visualized and appear well centered
and well positioned against the atrial septum. B,
Unique oblique view from below toward the supe-
rior vena cava, obtained to detect the junction of the
superior vena cava to the right atrium. There is no
obstruction of the superior vena cava from the
device (arrowheads). LA 5 left atrium; LV 5 left
ventricle; RA 5 right atrium; RV 5 right ventricle;
SVC 5 superior vena cava.
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device type. Balloon sizing to establish the stretched ASD
diameter has remained the gold standard in spite of the more
convenient echocardiographic measurement. This technique is
less reliable because many communications are not perfectly
round (4,14). Three patients in our study had a trivial residual
shunt that disappeared in two patients within 1 month and 3
months, respectively, after the procedure. It should be noted
that in all three patients the size of the device was 1 mm less
than the measured balloon-stretched ASD diameter. There-
fore, we believe that it is essential to choose a device identical
to the measured balloon-stretched diameter of the defect in
order to maximize the efficacy of this particular design.
A very important property of the Amplatzer is retrievability
while the device is still attached to the delivery cable, which
allows repositioning in case of misplacement, thus obviating
surgical removal. Most of the other devices, with the exception
of the clamshell septal occluder (4), are not retrievable or once
deployed it is very laborious to reposition or to remove them
(7–9,11,12). The Amplatzer prosthesis can be fully recaptured
into the sheath with the delivery cable. Because of its super-
elastic properties, the nitinol frame of the device retains its
initial shape even if it is deployed several times. Indeed
misplacement of both discs across the defect was encountered
in one of our patients and was easily corrected by withdrawing
and redeploying the device. An additional advantage of this
prosthesis are the two round disks. Devices with corners or
spokes may cause accidental injury of atrioventricular valves or
perforations of an intracardiac structure during disk deploy-
ment. Also, delayed perforations can occur. Furthermore,
complications previously reported, such as metal fatigue frac-
tures (15), structural failure or embolizations of the device
(4–7,16), atrial perforation (7,16) and atrioventricular valve
damage (7), were not observed in the present study, although
the follow-up is short.
As compared with other devices, the Amplatzer’s loading,
technical deployment and recapturing is simple, without com-
plicated mechanisms. This significantly reduces the procedural
and fluoroscopy time and shortens the learning curve of each
operator. Indeed the procedural (67.5 6 8.1 min) and
fluoroscopy (20.3 6 3.5 min) times in this study were very
short for this type of intervention. In the atrial septal defect
occlusion system experience in children, procedural times
ranged from 132 to 194 min and fluoroscopy times from 17
to 39 min (9).
Biplane transesophageal color Doppler echocardiography
was used in this study for guidance of transcatheter closure of
the ASDs. Echocardiographic imaging is superior to fluoros-
copy as it provides unique information regarding the anatomy
of the defect, the position of the device across the atrial septum
and its relation to adjacent cardiac structures (17,18). An
important benefit of the Amplatzer is its optimal echogenicity,
owing to its Nitinol mesh structure, which makes it easily
visible in the short-axis and longitudinal views of the device
and residual shunting can be precisely delineated.
Recently, three-dimensional transesophageal or trans-
thoracic echocardiography was used for patient selection and
guidance of transcatheter closure of ASDs (19,20). Three-
dimensional echocardiography displays the defect as a dynamic
structure whose size and morphology change with the cardiac
cycle, and its maximal diameter can be better appreciated
when the periphery of the defect is seen in an en-face view.
Additionally, one can visualize both atrial discs of the occlu-
sion device and their dynamic anatomic relation to the adja-
cent cardiac structures. In this study the use of three-
dimensional transthoracic echocardiography proved useful in
the preselection of patients and provided guidance of ASD
closure with the Amplatzer prosthesis.
Conclusions. Our results indicate that the Amplatzer is an
efficient prosthesis that can be safely used in children with
secundum ASDs. It is simple in construction, easy to deploy
and can be withdrawn and repositioned many times. Further
studies are required to establish its value in a larger number of
patients, for closure of larger ASDs and patent foramen ovale.
Furthermore, long-term follow-up is needed to exclude possi-
ble adverse side effects.
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